Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia
- PMID: 7541549
Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia
Abstract
Benign prostatic hyperplasia (BPH) and hypertension are both common conditions in older men. It is estimated that 20 to 41% of middle-aged to elderly men may have both. Alpha-1 adrenoceptor antagonists, such doxazosin, produce significant improvements in urine flow rate and symptoms in patients with BPH. The effect of doxazosin on urine flow rate and symptoms in hypertensive men with BPH is similar to that seen in normotensive men. By contrast, doxazosin produces a significant fall in blood pressure in hypertensive men, but has minimal effect in normotensives. Doxazosin is well tolerated, irrespective of blood pressure status. Thus, it can be concluded doxazosin is an effective and well tolerated treatment for BPH which appears to have additional benefits in the management of patients with concomitant hypertension.
Similar articles
-
Profile of doxazosin in patients with benign prostatic hyperplasia.Scand J Urol Nephrol Suppl. 1995;168:21-7. Scand J Urol Nephrol Suppl. 1995. PMID: 7541548 Review.
-
Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.Br J Clin Pract Suppl. 1994 May;74:23-8. Br J Clin Pract Suppl. 1994. PMID: 7519438
-
Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men.Urology. 1995 Aug;46(2):182-6. doi: 10.1016/s0090-4295(99)80191-5. Urology. 1995. PMID: 7542819 Clinical Trial.
-
Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension.BJU Int. 2006 Jan;97(1):90-5. doi: 10.1111/j.1464-410X.2006.05858.x. BJU Int. 2006. PMID: 16336335
-
Expanding role of alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia.Int J Clin Pract. 1998 Sep;52(6):402-7. Int J Clin Pract. 1998. PMID: 9894377 Review.
Cited by
-
Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH).Ther Clin Risk Manag. 2007 Mar;3(1):181-96. doi: 10.2147/tcrm.2007.3.1.181. Ther Clin Risk Manag. 2007. PMID: 18360626 Free PMC article.
-
Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo.Int Urol Nephrol. 2002;34(3):351-6. doi: 10.1023/a:1024487604631. Int Urol Nephrol. 2002. PMID: 12899226 Clinical Trial.
-
Doxazosin added to single-drug therapy in hypertensive patients with benign prostatic hypertrophy.J Clin Hypertens (Greenwich). 2001 Jul-Aug;3(4):218-23. doi: 10.1111/j.1524-6175.2001.00459.x. J Clin Hypertens (Greenwich). 2001. PMID: 11498652 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical